Alignment Healthcare (ALHC) Projected to Announce Earnings on Thursday

Alignment Healthcare (NASDAQ:ALHC) is expected to be releasing its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of $0.13 per share and revenue of $1.3067 billion for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 5:00 PM ET.

Alignment Healthcare (NASDAQ:ALHC) last announced its earnings results on Thursday, April 30th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.04. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.22 billion. Alignment Healthcare had a return on equity of 11.50% and a net margin of 0.47%.The business’s revenue was up 33.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.05) EPS. On average, analysts expect Alignment Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Alignment Healthcare Trading Down 3.4%

NASDAQ ALHC opened at $20.77 on Thursday. The business’s fifty day moving average is $19.43 and its 200-day moving average is $19.88. The company has a debt-to-equity ratio of 1.56, a current ratio of 1.58 and a quick ratio of 1.58. The stock has a market capitalization of $4.29 billion, a price-to-earnings ratio of 230.78, a PEG ratio of 2.90 and a beta of 1.05. Alignment Healthcare has a one year low of $11.63 and a one year high of $25.12.

Analyst Ratings Changes

ALHC has been the subject of a number of research analyst reports. Barclays decreased their price objective on shares of Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating for the company in a report on Tuesday, May 26th. KeyCorp reiterated an “overweight” rating on shares of Alignment Healthcare in a research note on Wednesday, June 10th. Wolfe Research started coverage on shares of Alignment Healthcare in a research report on Friday, April 17th. They set an “outperform” rating and a $24.00 target price for the company. Weiss Ratings upgraded shares of Alignment Healthcare from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Finally, Zacks Research cut shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.30.

Insider Buying and Selling

In other Alignment Healthcare news, insider Mark D. Kent bought 14,848 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was purchased at an average price of $13.31 per share, for a total transaction of $197,626.88. Following the completion of the transaction, the insider directly owned 14,848 shares of the company’s stock, valued at $197,626.88. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, President Dawn Christine Maroney sold 30,000 shares of Alignment Healthcare stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $19.55, for a total transaction of $586,500.00. Following the completion of the transaction, the president owned 947,313 shares of the company’s stock, valued at $18,519,969.15. The trade was a 3.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,039,951 shares of company stock worth $19,976,967 in the last quarter. 5.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Wellington Management Group LLP grew its stake in Alignment Healthcare by 26.9% in the 4th quarter. Wellington Management Group LLP now owns 14,070,893 shares of the company’s stock valued at $277,900,000 after buying an additional 2,981,166 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Alignment Healthcare by 0.6% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock worth $249,715,000 after acquiring an additional 79,268 shares in the last quarter. Invesco Ltd. lifted its position in shares of Alignment Healthcare by 38.9% during the fourth quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock worth $122,501,000 after acquiring an additional 1,735,962 shares in the last quarter. 8 Knots Management LLC lifted its position in shares of Alignment Healthcare by 6.4% during the second quarter. 8 Knots Management LLC now owns 5,015,881 shares of the company’s stock worth $70,222,000 after acquiring an additional 300,409 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Alignment Healthcare by 14.3% in the fourth quarter. State Street Corp now owns 3,668,602 shares of the company’s stock worth $72,455,000 after acquiring an additional 460,154 shares during the period. 86.19% of the stock is owned by institutional investors.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.